An epigenetic approach to MASLD has been proposed in the paper by Xu et al. [98], where the authors targeted p300 histone acetyltransferase (p300) as a major epigenetic transcriptional mechanism underlying MASLD pathogenesis. The gene discussed is EP300; the disease is metabolic dysfunction-associated steatotic liver disease.